3 results
The objectives of this are to establish the safety, tolerability, and efficacy of VRDN-001, and the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of VRDN-001 in HV and TED patients over a dose range of 3.0 to 20.0 mg/kg.
Primary objectives: 1. To assess the effect of experimental immunization with GA2 sporozoites by mosquito bite with and without co-administration of different adjuvants on the pre-patent period after controlled human malaria infection (CHMI).2. To…
In this study we will investigate how quickly and to what extent ralmitaront is absorbed, transported, and eliminated from the body (this is called pharmacokinetics). Ralmitaront is radioactively labelled with carbon 14 (14C). In this way…